Posts by tag
prostate cancer
Wake-up call to offer equal access to life-prolonging treatments in metastatic prostate cancer
Less than one third of men with metastatic castration-sensitive prostate cancer (mCSPC) received established treatment intensification by 2018 that had been demonstrated to extend survival. The US study evaluating real-world utilization of advanced therapies, abstract 5073, released in advance of…
Study suggests tackling loneliness could help reduce cancer in middle-aged men
Loneliness among middle-aged men is associated with increased risks of developing cancer. The longitudinal Finnish study, published in the May issue of Psychiatry Research, additionally found mortality was higher among male cancer patients who were unmarried, widowed or divorced than…
PSA population screening is back in favour: here’s why
Five years ago, the idea of national screening programmes for prostate cancer had gone cold. The benefits of PSA (prostate specific antigen) blood testing, introduced as a screening tool in the 1980s, had long been fiercely debated. But by 2015…
Study brings mass biparametric MRI screening for prostate cancer a step closer
Using biparametric (bp) magnetic resonance imaging (MRI) to screen for prostate cancer identified twice as many clinically significant cancers as standard prostate-specific antigen (PSA) tests. Moreover, the UK study, reported in JAMA Oncology (11 February), found bpMRI improved detection of…
Coffee may protect against prostate cancer
Drinking several cups of coffee every day may be linked to a lower risk of developing prostate cancer. The meta-analysis study, published in BMJ Open, (11 January) found that each additional daily cup of coffee was associated with a 1%…
Berlin pilot project brings precision care to the peripheries
A decade ago, men with metastatic prostate cancer could typically expect to live two to three years. The arrival of new hormone drugs such as abiraterone radically changed the odds, and the equation is now changing every day, as trials…
Prolonged ADT use in prostate cancer increases CV mortality: A need for cardiovascular protection
Prolonged androgen deprivation therapy (ADT) exposure was found to be associated with reduced cardiorespiratory fitness (CRF) and increased cardiovascular (CV) mortality. The study, published in JACC: CardioOncology, emphasizes the need to consider CV surveillance and risk modification for men both…
Gut microbiome positively influences abiraterone response in prostate cancer
Abiraterone acetate (AA), an agent used in castrate-resistant prostate cancer, promotes a shift towards health-associated, anti-inflammatory gut commensal bacteria, finds a study in Nature Communications. “These findings clearly demonstrate that the gut microbiome is playing a role in treatment response,”…
Metastatic prostate cancer: cabazitaxel shows quality of life benefits over both abiraterone and enzalutamide
In addition to previously reported survival benefits, the taxane cabazitaxel improved quality of life in patients with advanced metastatic prostate cancer compared to the androgen signalling targeted inhibitors abiraterone and enzalutamide, reports the latest analysis of the CARD trial (Fizazi…
Link between COVID-19 and prostate cancer raises possibility of new treatments
The overlapping biology identified between the molecular pathogenesis of COVID-19 and prostate cancer raises the possibility of repurposing drugs, including androgen deprivation therapy, for treating COVID-19, suggests a review in Nature Communications Biology, published 8 July. In the review the…